US › Healthcare

MetaVia Inc. (MTVA)

US · Healthcare · Biotechnology

$1.46-1.35%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-3.8M
Profit YoY
-4.1%
EPS
$-0.79
EPS estimate
$-0.75

EPS came in at -0.79 against a street estimate of -0.75 — a miss of 5.3%.

Key statistics

Market cap
$7.3M
Forward P/E
0.0
P/B
0.81
Book value
$1.76
EPS (TTM)
$-4.21
52-week high
$19.03
52-week low
$0.97
50-day MA
$1.95
200-day MA
$4.11
Beta
0.97

Analyst view

Analysts rate MetaVia Inc. a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $19.33.

Shareholding

Insiders
36.50%
Institutions
13.38%

Largest institutional holders

FundStake
Geode Capital Management, LLC0.65%
Vanguard Group Inc0.39%
Jane Street Group LLC0.21%
Aries Wealth Management0.19%
Vanguard Fiduciary Trust Co0.13%
Tower Research Capital LLC0.05%
Vanguard Capital Management, LLC0.04%
BlackRock Inc0.01%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for MetaVia Inc. — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.